Chicago, GenomeWeb — A new study by researchers from Memorial Sloan Kettering Cancer Center has demonstrated the predictive power of an AR - V7 protein expression test using Epic Sciences» non-EPCAM-based
circulating tumor cell detection platform, which could help guide treatment decisions for men with metastatic castration - resistant prostate cancer.
Not exact matches
«This development has the potential to enable earlier
detection of solid
tumors through a simple blood draw by substantially improving our ability to detect very low quantities of
circulating DNA derived from
tumor cells,» says corresponding author Hunter Underhill, M.D., Ph.D., who initiated the research while in the lab of senior author Jay Shendure, M.D., Ph.D., a professor in genome sciences at the University of Washington.
Adds Liu: «With metastatic cancers accounting for around 90 % of deaths from solid
tumors, the hope is that one day a device that can enable the analysis of single
tumor cells circulating in the blood could make a big difference in early diagnosis,
detection and monitoring of numerous types of cancer, without invasive biopsies.»
The technique, described in Biomaterials, uses gold nanoparticles and Raman scattering, a technology previously developed by Qian and Nie for cancer
cell detection (2007 Nature Biotech paper, 2011 Cancer Research paper on
circulating tumor cells).
Methods for detecting
tumor cells and DNA
circulating in bodily fluids are currently under intense investigation for early
detection and cancer diagnostics; however, no existing technology meets the high sensitivity and specificity requirements needed to attain these goals.
We conducted a meta - analysis in nonmetastatic breast cancer patients treated by neoadjuvant chemotherapy (NCT) to assess the clinical validity of
circulating tumor cell (CTC)
detection as a prognostic marker.